LAUSR

Key Points Question Can the outcomes of pivotal trials conducted among patients with extensive-stage small cell lung cancer (ES-SCLC) be applied in a clinical practice setting? Findings In this cohort study of 207 patients with ES-SCLC who received chemoimmunotherapy as the first-line treatment, the overall treatment outcome was comparable to that reported in pivotal clinical trials. However, treatment outcomes after chemoimmunotherapy might differ between trial-eligible and trial-ineligible patients. Meaning These findings suggest that it may be useful to consider trial-eligibility criteria for clinical decision-making in a clinical practice setting; further studies using high-quality clinical practice data are required to elucidate the association of eligibility criteria with clinical outcomes.